The AI drug discovery company’s reorganization will include laying off around 180 employees and dropping its atopic dermatitis candidate BEN-2293 in an effort to save nearly $56 million.
Tag Archive for: Atopic dermatitis
Merck will acquire immune-focused Prometheus Biosciences for approximately $10.8 billion, scoring five clinical and pre-clinical candidates for inflammatory bowel and immune-mediated diseases.
Regeneron Pharmaceuticals Inc. reported a better-than-expected fourth-quarter profit on Friday, as strong demand for eczema drug Dupixent helped shield a drop in U.S. sales of its blockbuster eye drug, Eylea.
In a fireside chat at the 41st J.P. Morgan Healthcare Conference in San Francisco, CEO Rick Gonzalez said AbbVie is well-positioned for continued growth.
Following a banner year marked by the approval and launch of its diabetes drug Mounjaro, Eli Lilly revealed at the 41st J.P. Morgan Healthcare Conference that it was preparing for another big year.
While reporting positive third-quarter financials, AbbVie announced it is halting the development of cedirogant (ABBV-157), while also providing updates on Skyrizi, Rinvoq and Humira.
AbbVie may have doubled in size since the Allergan acquisition, but nearly half the company’s revenue, and a large chunk of its potential future growth, are still coming from a familiar place.
Following its Play to Win strategy, Sanofi looks to the future with a new corporate identity and charitable foundations.
LEO Pharma A/S, a global leader in medical dermatology, has launched AD Days Around the World, a global disease awareness campaign that highlights the experiences of people living with atopic dermatitis (AD) – the most common form of eczema.
Shares of ChemoCentryx are skyrocketing in premarket trading after the company announced it will be acquired by Amgen in a $4 billion deal that will bring Tavneos, a first-in-class treatment for ANCA-associated vasculitis, into the company’s portfolio.